This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. 

Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.

To learn more about the topics in this episode: 
No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis
Fierce Biotech Layoff Tracker 2024

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. 
Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/biopharma-layoffs-dont-see-reprieve-q1-2024-fierce-biotech-analysis">No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024">Fierce Biotech Layoff Tracker 2024</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Deep dive: Biopharma layoffs in Q1

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge.

In this episode of “The Top Line,” Fierce Biotech’s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators may approach misuse of nonpublic information in prediction markets, why biopharma could face heightened scrutiny and what companies should be doing now to reduce their risk.

To learn more about the topics in this episode: 
Betting on biotech: Prediction markets set sights on clinical trials

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge.
In this episode of &ldquo;The Top Line,&rdquo; Fierce Biotech&rsquo;s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators may approach misuse of nonpublic information in prediction markets, why biopharma could face heightened scrutiny and what companies should be doing now to reduce their risk.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/betting-biotech-prediction-markets-set-sights-clinical-trials" data-processed-url="true">Betting on biotech: Prediction markets set sights on clinical trials</a></li>
</ul>

Inside the growing world of biopharma prediction markets

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia sits down with Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter, Ph.D., to discuss the significance of Revolution Medicines’ recent pancreatic cancer approval, Verastem’s work in the RAS-targeting space and how the company is trying to improve on existing approaches.

To learn more about the topics in this episode: 


FDA greenlights Revolution Medicines' pancreatic cancer gamechanger 


As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground 


ASCO: Revolution Medicines confident in RAS leadership as rivals square up 


AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises 


Fierce 50 of 2026: Breakthrough honoree Verastem Oncology


Fierce 50 of 2026: Breakthrough honoree Revolution Medicines 

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; Fierce Biotech&rsquo;s Darren Incorvaia sits down with Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter, Ph.D., to discuss the significance of Revolution Medicines&rsquo; recent pancreatic cancer approval, Verastem&rsquo;s work in the RAS-targeting space and how the company is trying to improve on existing approaches.
To learn more about the topics in this episode:&nbsp;
<ul>
<li>
<a href="https://www.fiercepharma.com/pharma/fda-greenlights-revolution-medicines-pancreatic-cancer-gamechanger">FDA greenlights Revolution Medicines' pancreatic cancer gamechanger</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercepharma.com/pharma/revmed-preps-historic-pancreatic-cancer-launch-questions-linger-ground">As RevMed preps for &lsquo;historic&rsquo; pancreatic cancer launch, questions linger on the ground</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/asco-revolution-medicines-confident-ras-leadership-rivals-square">ASCO: Revolution Medicines confident in RAS leadership as rivals square up</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/aacr-revolution-rolls-pancreatic-cancer-ras-wave-rises">AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises</a>&nbsp;
</li>
<li>
<a href="https://www.fiercepharma.com/fierce-50/verastem-oncology">Fierce 50 of 2026: Breakthrough honoree Verastem Oncology</a>
</li>
<li>
<a href="https://www.fiercepharma.com/fierce-50/revolution-medicines">Fierce 50 of 2026: Breakthrough honoree Revolution Medicines</a>&nbsp;
</li>
</ul>

The future of RAS inhibitors

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vaccine science, improving health literacy and expanding representation in medicine.

In this episode of “The Top Line,” Fierce Editor-in-Chief Ayla Ellison looks at the stories behind several of this year’s honorees, including Revolution Medicines’ work targeting RAS, the protein-design research of David Baker, Ph.D., and Michael Osterholm, Ph.D.’s, decision to put plans to step back from public health on hold. The episode also explores the work of Lisa Fitzpatrick, M.D., Hip Hop Public Health, Eric Topol, M.D., and Mary Owen, M.D., and the problems they have chosen to keep working on.

The <a href="https://www.fiercepharma.com/collection/fierce-50-2026">2026 Fierce 50</a> includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vaccine science, improving health literacy and expanding representation in medicine.
In this episode of &ldquo;The Top Line,&rdquo; Fierce Editor-in-Chief Ayla Ellison looks at the stories behind several of this year&rsquo;s honorees, including Revolution Medicines&rsquo; work targeting RAS, the protein-design research of David Baker, Ph.D., and Michael Osterholm, Ph.D.&rsquo;s, decision to put plans to step back from public health on hold. The episode also explores the work of Lisa Fitzpatrick, M.D., Hip Hop Public Health, Eric Topol, M.D., and Mary Owen, M.D., and the problems they have chosen to keep working on.

Deep dive: Biopharma layoffs in Q1

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips